NCT05192395View on ClinicalTrials.gov

A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

April 15, 2022

Primary Completion Date

May 24, 2022

Study Completion Date

May 24, 2022

Conditions
Healthy
Interventions
DRUG

DWJ1525

DWJ1525

DRUG

DWP16001

DWP16001

DRUG

DWC202101

DWC202101

Trial Locations (1)

Unknown

CHA unuversity bundang medical center, Seongnam

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY

NCT05192395 - A Crossover Study of DWJ1525 to Evaluate the Safety and Pharmacokinetic Properties in Healthy Volunteers | Biotech Hunter | Biotech Hunter